ReviewCirculation research2009
Human studies of angiogenic gene therapy.
Review in Circulation research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis.Circulation research · 2016Pooled it
- Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication.Therapeutic advances in cardiovascular disease · 2018Trial
- Intramyocardial, autologous CD34+ cell therapy for refractory angina.Circulation research · 2011Trial
- METTL14-dependent NExperimental & molecular medicine · 2026Article
- Ferroptosis in Vascular Diseases: A Mechanistic and Immunological Perspective on Therapeutic Targeting.Antioxidants (Basel, Switzerland) · 2026Review
- Exploring the role of HIF-1α on pathogenesis in Alzheimer's disease and potential therapeutic approaches.Inflammopharmacology · 2025Review
- Lipocalin 2 deficiency impacts angiogenesis after ischemia in vivo and in vitro.Vascular biology (Bristol, England) · 2025Article
- Sustained capillary enlargement induced by angiogenic gene therapy does not support post-ischemic muscle recovery of hyperlipidemic mice.Frontiers in bioengineering and biotechnology · 2025Article
- What Is the Best Experimental Model for Developing Novel Therapeutics in Peripheral Artery Disease?Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- The Combined Delivery of theCurrent issues in molecular biology · 2024Article
- Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction.Materials today. Bio · 2024Review
- Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema.EMBO molecular medicine · 2024Article
- Histidine Triad Nucleotide-Binding Protein 1 Improves Critical Limb Ischemia by Regulating Mitochondrial Homeostasis.Nutrients · 2023Article
- Induction of Angiogenesis by Genetically Modified Human Umbilical Cord Blood Mononuclear Cells.International journal of molecular sciences · 2023Article
- Mesenchymal stem cell-based therapy for non-healing wounds due to chronic limb-threatening ischemia: A review of preclinical and clinical studies.Frontiers in cardiovascular medicine · 2023Review
- KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation.Journal of translational medicine · 2022Article
- Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.European journal of medical research · 2022Review
- Increased estimated remnant-like particle cholesterol is associated with impaired coronary collateralization in patients with coronary chronic total occlusions.Diabetology & metabolic syndrome · 2022Article
- Study of Alveolar Bone Remodeling Using Deciduous Tooth Stem Cells and Hydroxyapatite by Vascular Endothelial Growth Factor Enhancement and Inhibition of Matrix Metalloproteinase-8 Expression in vivo.Clinical, cosmetic and investigational dentistry · 2022Article
- Modulation of VEGFA Signaling During Heart Regeneration in Zebrafish.Methods in molecular biology (Clifton, N.J.) · 2022Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite significant advances in medical, interventional, and surgical therapy for coronary and peripheral arterial disease, the burden of these illnesses remains high. To address this unmet need, the science of therapeutic angiogenesis has been evolving for almost two decades. Early preclinical studies and phase I clinical trials achieved promising results with growth factors administered as recombinant proteins or as single-agent gene therapies, and data accumulated through 10 years of clinical trials indicate that gene therapy has an acceptable safety profile. However, more rigorous phase II and phase III clinical trials have failed to unequivocally demonstrate that angiogenic agents are beneficial under the conditions and in the patients studied to date. Investigators have worked to understand the biology of the vascular system and to incorporate their findings into new treatments for patients with ischemic disease. Recent gene- and cell-therapy trials have demonstrated the bioactivity of several new agents and treatment strategies. Collectively, these observations have renewed interest in the mechanisms of angiogenesis and deepened our understanding of the complexity of vascular regeneration. Gene therapy that incorporates multiple growth factors, approaches that combine cell and gene therapy, and the administration of "master switch" agents that activate numerous downstream pathways are among the credible and plausible steps forward. In this review, we examine the clinical development of angiogenic gene therapy, summarize several of the lessons learned during the conduct of these trials, and suggest how this prior experience may guide the conduct of future preclinical investigations and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.